Novartis | NVS - Operating Profit


Novartis reported $4.58B in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bausch Health Companies USD 719M 2M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Canopy Growth CAD -14.3M 3.18M Sep/2025
Corcept Therapeutics USD 10.22M 16.46M Sep/2025
Drreddys Laboratories INR 14.33B 2.51B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
J&J USD 5.59B 1.81B Dec/2025
Merck USD 6.24B 318M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Novartis USD 4.58B 879M Sep/2025
Pacira USD 13.15M 2.92M Sep/2025
Perrigo USD 93.4M 37.8M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Phibro Animal Health USD 25.53M 7.83M Dec/2024
Prestige Brands USD 82.49M 2.82M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sanofi EUR 1.5B 2.29B Dec/2025
Supernus Pharmaceuticals USD -60.18M 72.32M Sep/2025
Zoetis USD 835M 101M Dec/2025